These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8629267)

  • 1. [Malignant hematologic diseases].
    Fehr J
    Ther Umsch; 1996 Feb; 53(2):81. PubMed ID: 8629267
    [No Abstract]   [Full Text] [Related]  

  • 2. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome.
    Zipursky A; Brown EJ; Christensen H; Doyle J
    Clin Lab Med; 1999 Mar; 19(1):157-67, vii. PubMed ID: 10403079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferons in the treatment of hematological diseases].
    Jantunen E; Nousiainen T
    Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hospital infections in patients with hematologic diseases].
    Sidorova LD; Bondar' IA
    Probl Gematol Pereliv Krovi; 1982 May; 27(5):3-5. PubMed ID: 7100143
    [No Abstract]   [Full Text] [Related]  

  • 5. Hematologic problems in the elderly.
    Mazza JJ
    Wis Med J; 1983 Sep; 82(9):13-6. PubMed ID: 6649671
    [No Abstract]   [Full Text] [Related]  

  • 6. Overt gastrointestinal bleeding in haematologic neoplasms.
    Soylu AR; Buyukasik Y; Cetiner D; Buyukasik NS; Koca E; Haznedaroglu IC; Ozcebe OI; Simsek H
    Dig Liver Dis; 2005 Dec; 37(12):917-22. PubMed ID: 16243010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
    Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
    Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France.
    Hausfater P; Cacoub P; Sterkers Y; Thibault V; Amoura Z; Nguyen L; Ghillani P; Leblond V; Piette JC
    Am J Hematol; 2001 Jul; 67(3):168-71. PubMed ID: 11391713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hematologic pathology and immunodepression outside of HIV infection: modification of the histopathologic semiology].
    Molina TJ; Le Tourneau A; Damotte D; Diebold J; Audouin J
    Ann Pathol; 2008 Nov; 28 Spec No 1(1):S120-1. PubMed ID: 18984287
    [No Abstract]   [Full Text] [Related]  

  • 10. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
    Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
    Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy in malignant blood diseases].
    Ikkala E
    Duodecim; 1967; 83(4):233-41. PubMed ID: 5343193
    [No Abstract]   [Full Text] [Related]  

  • 14. Malignant disorders of megakaryocytes.
    Cripe LD; Hromas R
    Semin Hematol; 1998 Jul; 35(3):200-9. PubMed ID: 9685166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Registration of hematological disorders by the Kyushu Hematology Organization for Treatment (K-HOT) Study Group].
    Kawano R; Utsunomiya A; Matsuoka H; Kawano F; Ikeda S; Izumi Y; Tsukada J; Shibuya T; Okamura S; Uike N; Nagano M; Tamura K;
    Rinsho Ketsueki; 2004 Jun; 45(6):478-80. PubMed ID: 15287525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum thrombopoietin level in various hematological diseases.
    Usuki K; Tahara T; Iki S; Endo M; Osawa M; Kitazume K; Kato T; Miyazaki H; Urabe A
    Stem Cells; 1996 Sep; 14(5):558-65. PubMed ID: 8888496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders.
    Zhang LJ; Shin ES; Yu ZX; Li SB
    Chin Med J (Engl); 2007 Nov; 120(22):2002-5. PubMed ID: 18067786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vasculitis and malignant diseases].
    Gran JT
    Tidsskr Nor Laegeforen; 1997 Apr; 117(11):1627-9. PubMed ID: 9198948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Philadelphia chromosome-negative chronic myeloproliferative disease.
    Thiele J
    Am J Clin Pathol; 2009 Aug; 132(2):261-80. PubMed ID: 19605821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.